Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies in oncology and obesity. Its pipeline centers on CRB-701, an antibody-drug conjugate targeting Nectin-4 in cancer, and CRB-913, a peripherally restricted CB1 receptor inverse agonist designed for obesity treatment.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIncludes CRB-701 and related cancer-focused development programs targeting solid tumors.
Includes CRB-913, a CB1 receptor program aimed at weight-loss treatment.
Includes CRB-601 and other early-stage biologics under development.
Internal R&D, clinical operations, and regulatory development activities supporting the pipeline.
Customers
Corbus does not currently sell commercial products, so its near-term 'customers' are primarily clinical investigators, trial sites, regulators, and future licensing or commercialization partners. If approved, its therapies would be used by oncology and obesity patients through physicians and healthcare systems, but today the business is funded by capital markets rather than product buyers.
Hospitals, investigators, and CROs that support enrollment, dosing, monitoring, and data collection for CRB-701, CRB-913, and CRB-601.
FDA and comparable agencies that determine whether product candidates can advance to later-stage trials or approval.
Potential licensing or collaboration partners that may fund development, share risk, or commercialize assets.
Oncologists who would prescribe CRB-701 if it reaches approval and demonstrates clinical benefit.
Physicians treating obesity who could adopt CRB-913 if safety and efficacy are validated.
Strategy
Corbus is focused on advancing a small number of high-conviction pipeline assets rather than managing a broad commercial portfolio. Near-term strategy is to progress CRB-701 and CRB-913 through clinical development, maintain manufacturing readiness through third parties, and secure additional financing to fund multi-year development work.
The oncology asset is a core value driver and needs human data to support partnering or later-stage trials.
The obesity market is large, but the program must prove safety and tolerability to differentiate from competitors.
The company has no product revenue and expects continued operating losses, so capital access is essential.
Geography
Corbus is headquartered in Norwood, Massachusetts and operates as a U.S.-based clinical-stage company. The reports indicate most cash and operating activity are concentrated in the United States, while clinical development and regulatory interactions can extend to other countries through trials, vendors, and future commercialization pathways.
Risks
Corbus is exposed to the classic risks of an early-stage biotech: no product revenue, high cash burn, and uncertainty that clinical candidates will succeed or reach approval. Its dependence on third-party manufacturers, CROs, and regulators means delays or quality issues can materially slow development, while competition in both oncology and obesity is intense.
- Lack of product revenueImpact: CriticalLikelihood: High
The company has not commercialized any products, so value depends on future clinical and regulatory success.
Exposure: All current operations
- Funding and dilution riskImpact: HighLikelihood: High
Ongoing R&D and clinical costs require repeated capital raises, which may be unavailable or dilutive.
Exposure: Equity financing and cash runway
- Clinical development failureImpact: HighLikelihood: Medium
Drug candidates may not show sufficient safety or efficacy in trials, which would impair commercialization prospects.
Exposure - Third-party manufacturing and trial executionImpact: HighLikelihood: Medium
The company relies on external manufacturers and service providers to produce clinical material and run studies.
Exposure - Competitive pressureImpact: MediumLikelihood: Medium
Larger biopharma companies and other biotech firms are pursuing similar oncology and obesity mechanisms.
Exposure - Geopolitical and trade exposureImpact: MediumLikelihood: Medium
Management disclosed that U.S.-China trade relations and broader geopolitical conditions could affect operations and results.
Exposure: Global supply and development ecosystem
Accounting
Judgemental itemsClinical and manufacturing services are often billed after work is performed, requiring management estimates at period-end.
Impact: Can shift expense timing between quarters
As a development-stage company, equity awards are used to retain talent and create non-cash expense.
Impact: Affects operating loss and diluted share metrics
The Jenrin agreement includes potential development and regulatory milestones that may become payable as programs advance.
Impact: Can create contingent liabilities and cash outflows
Interest and investment income depends on portfolio yields and market conditions.
Impact: Affects other income and liquidity presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Corvus Pharmaceuticals, Inc.
CRVS · Pharmaceutical Preparations
Crescent Biopharma, Inc
CBIO · Pharmaceutical Preparations
NextCure, Inc.
NXTC · Pharmaceutical Preparations
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Terns Pharmaceuticals, Inc.
Pharmaceutical Preparations
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Last updated: 24/09/2026